FDA Expands Indication for Octapharma’s WILATE to Hemophilia A
The U.S. Food and Drug Administration (FDA) has approved WILATE for treatment of adults and adolescents with hemophilia A for routine prophylaxis.
The Challenge of Cold Chain Logistics
While some of the guidelines for the transportation, handling, storage and delivery of temperaturesensitive medications are basic and vague, advances in technology help to ensure these drugs are
safe and effective when they reach their site of administration.
Establishing an Antimicrobial Stewardship Program
The adoption of ASPs has resulted in a reduction of antimicrobial expenditures, but stopping the tide of multidrug-resistant organisms depends on leadership’s commitment to track data down to the patient level.
Short-Dated Products: Reducing Unsalable Returns and Supply Chain Waste
The glut of soon-to-expire products within the pharmaceutical supply chain is a costly problem impacting multiple stakeholders, but smart technology and innovative inventory management systems offer cost-saving solutions.
Octapharma Introduces New SCIG Product and IgCares Program
Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) at the Immune Deficiency Foundation (IDF) National Conference in June.
FDA Approves Octaplas to Treat Pediatric Patients Who Require Multiple Coagulation Factor Replacement
A revised product label for Octapharma USA’s Octaplas (pooled plasma [human] solvent/detergent treated solution for intravenous infusion) to treat critically ill pediatric patients who require replacement of multiple coagulation factors has been approved by the U.S. Food and Drug Administration (FDA).
$1 Billion Grant Awarded to Fight Addiction and Chronic Pain
The National Institutes of Health (NIH) has awarded $945 million to battle addiction and chronic pain.
Anti-Influenza Hyperimmune Immune Globulin Not Effective in Hospitalized Adults with Influenza Infection
A trial was conducted to assess the safety and efficacy of hIVIG (in conjunction with standard care) in adults hospitalized with laboratory-confirmed influenza A or B infection.
Emicizumab Prophylaxis Combined with ITI Effective in Pediatric Patients with Severe Hemophilia A and Inhibitors
Researchers at Emory University have described successful use of a novel treatment regimen, dubbed the “Atlanta Protocol,” that involved concomitant use of Hemlibra (emicizumab) prophylaxis and immune tolerance induction (ITI) to treat pediatric patients with severe hemophilia A and inhibitors.
FDA Approves Expanded Use of Doptelet to Treat Thrombocytopenia
FDA has approved an expanded indication for Dova Pharmaceuticals’ Doptelet (avatrombopag) to treat adults with chronic immune thrombocytopenia.
